Influenza Therapeutics Market, by Drug Type, Virus Type, Age Group and Region | Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Influenza is an infection that is characterized by sudden onset of fever, headache, sore throat, non-productive cough, and rhinitis. There are four types of influenza virus such as A, B, C, and D. Influenza A and B virus are the most common virus that causes illness in humans. Moreover, prolonged influenza infections can cause severe complications such as pneumonia, bronchitis, acute respiratory distress, secondary bacterial infections, and cardiovascular complications.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2443
Influenza Therapeutics Market: Drivers
Increasing drug approvals for the treatment of influenza is projected to drive the influenza therapeutics market growth. For instance, in October 2018, Roche announced that the U.S. Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older.
A growing number of clinical pipeline studies are projected to boost the influenza therapeutics market growth during the forecast period. For instance, in January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the treatment of uncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral drug, used in the treatment of intestinal parasitic infections caused by Cryptosporidium parvam and Giardia lamblia. This study is expected to be completed in April 2019.
Moreover, in November 2018, Henry M. Jackson Foundation for the Advancement of Military Medicine, initiated phase 4 clinical trial study for egg-based influenza vaccines to study the realistic evaluation of influenza vaccine effectiveness in active duty members, military retirees, and other Department of Defense (DOD) beneficiaries.
Furthermore, increasing initiatives by various sponsors to conduct phase 1 clinical trial to study the safety parameter of anti-influenza drugs is projected to drive the market growth. For instance, in October 2018, Emory University started a phase 1 clinical trial for the seasonal influenza vaccine. The study has been conducted to evaluate the impact of imprinting and repeated influenza vaccination on adaptive immunity, transcriptomics, and metabolomics. The study is expected to be completed in July 2020.
Influenza Therapeutics Market: Restraints
Influenza vaccines have several limitations such as long production times, limited vaccine capacity, moderate efficacy in certain people, and lack of cross-reactivity, which is expected to restrain the growth of the influenza therapeutics market during the forecast period. Moreover, growing concerns among people regarding the side effects of vaccines hamper the growth of the influenza therapeutic market. For instance, in October 2018, according to the National Opinion Research Centre (NORC) at the University of Chicago survey, around 43% of the adults were vaccinated and 14% plans to receive the flu shot. However, around 41% of the American people reported that they are not vaccinated and do not intend to get vaccinated, as adults were most likely to cite concerns about the side effects of the vaccine.
Influenza Therapeutics Market: Regional Analysis
On the basis of region, the global influenza therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the market, and this can be attributed to the high presence of key players such as GlaxoSmithKline plc and Hoffmann-La Roche Ltd. The regulatory agencies in the region select influenza viruses that are required for developing the influenza vaccine. In March 2018, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) conducted a meeting to select the influenza viruses for the composition of the influenza vaccine. In the meeting, VRBPAC recommended the trivalent formulation of influenza vaccines for influenza A including A/Michigan/45/2015 (H1N1) pdm09-like virus, A/Singapore/INFIMH-16–0019/2016 (H3N2)-like virus, and B/Colorado/06/2017-like virus (B/Victoria lineage). The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain: a B/Phuket/3073/2013-like virus (B/Yamagata lineage).
Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/influenza-therapeutics-market-2443
Asia Pacific is also projected to experience significant growth in the influenza therapeutics market, due to increasing initiatives by the Asia-Pacific Alliance for the Control of Influenza (APACI), to reduce the burden of influenza by enhancing control measures and boosting pandemic preparedness in the region, through the provision of educational information and activities.
Europe have also gained significant position in the market, owing to increasing initiatives by European Medical Association (EMA) during an influenza pandemic season leading to continuous monitoring of safety of centrally authorized pandemic influenza vaccines and antiviral medicines, and fast-track review of data for the authorization of pandemic influenza vaccines for use in all EU Member States. Also, a growing number of public awareness programs regarding the prevention and diagnosis of influenza has resulted in significant growth of the influenza therapeutics market in this region.
Key players operating in the global influenza therapeutic market include Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., Atriva Therapeutics Gmbh, Texas Medical Center, Life Science Austria (LISA), GE Healthcare Life Sciences, Sanofi Pasteur SA and Mylan, Inc.
Influenza Therapeutics Market: Taxonomy
By Drug Type
- Baloxavir Marboxil
- Quadrivalent Flu Vaccines
- Trivalent Flu Vaccines
By Virus Type
- Influenza Virus Type- A
- Influenza Virus Type-B
By Age Group
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire